Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

NCT03334812 | Terminated Phase 2 Results

• 1 other identifier: CLNA043X2201
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study was to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a single intra-articular (i.a.) administration of LNA043 in regenerating the articular cartilage of the knee, in a standardized clinical scenario of acute cartilage defect. The study aimed at characterizing the mechanism of action of LNA043

Conditions

Knee Cartilage Lesion

Keywords

cartilage lesion, ACI

Outcome Measures

Primary Outcomes (2)

• Change From Baseline in GAG Content

  Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content were assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB and the defect to be treated (DTBT or main lesion) to healthy weight bearing region (HWB), i.e. DTBT/HWB was of major interest

  Baseline, Week 4

• Bi-layer Collagen Organization Based on MRI Measurements

  MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the surgically created defect (SCD) and defect to be treated (DTBT) cartilage regions.

  Week 4

Secondary Outcomes (7)

• Change From Baseline in International Cartilage Repair Society (ICRS) Scoring

  Week 4

• Percentage of Donor Site Refilling Based on MRI Measurements.

  Baseline, Week 4, Week 12 and Week 28

• Change From Baseline in GAG Content

  Baseline, Week 12 and Week 28

• Bi-layer Collagen Organization Based on MRI Measurements

  Week 12 and Week 28

• PK Profile of LNA043 and of AngPTL3 in Serum Cmax

  4 weeks

Study Arms (4)

LNA043 20mg/ml

EXPERIMENTAL

LNA043 20mg/ml single dose

Biological: LNA043

Matching placebo to 20mg

PLACEBO COMPARATOR

Matching placebo to 20mg/3ml, single dose

Biological: placebo to LNA043

LNA043 40mg/ml

EXPERIMENTAL

LNA043 40mg/ml single dose

Biological: LNA043

Matching placebo to 40mg

PLACEBO COMPARATOR

Matching placebo to 40mg/4ml, single dose

Biological: placebo to LNA043

Interventions

LNA043 BIOLOGICAL

LNA043 Single dose

LNA043 20mg/ml; LNA043 40mg/ml

placebo to LNA043 BIOLOGICAL

placebo to LNA043 single dose

Matching placebo to 20mg; Matching placebo to 40mg

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Written informed consent must be obtained before any assessment is performed
• Patient is ≥18 and≤ 50 years old at time of screening
• Patient has a body mass index (BMI) \<30 kg/m2 at screening
• Patient has a localized articular cartilage defect of the knee and is scheduled for an ACI procedure
• Able to communicate well with the investigator, to understand and comply with the requirements of the study.

You may not qualify if:

• Patient has radiologically apparent degenerative joint disease in the target knee as determined by Kellgren and Lawrence grade ≥2 based on X-ray evaluation performed within 6 months from screening
• Patient has unstable knee joint or insufficiently reconstructed ligaments, based on medical history and physical examination by the investigator.
• Patient scheduled for a concomitant articular surgical procedure (e.g., anterior cruciate ligament reconstruction) other than debridement or partial meniscectomy
• Patient has malalignment (valgus- or varus-deformity) in the target knee ≥ 5° based on based on X-ray evaluation performed within 6 months from screening.at screeningmedical history. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior projection.
• Patient has a known autoimmune disease, inflammatory arthropathy (including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, CPPD, gout), active acute or chronic infection of the joint, recent Lyme disease to the knee, systemic cartilage disorder, or a known systemic connective tissue disease.
• Patient has had surgical treatment of the target knee using autologous osteochondral transplantation/mosaicplasty within 12 months prior to screening (Note: prior diagnostic arthroscopy with debridement and lavage, meniscal surgery, microfracture, anterior cruciate ligament reconstruction, and extra-articular surgery e.g., high-tibial osteotomy are acceptable).
• Patient is unable to undergo magnetic resonance imaging (MRI) or presents absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).
• Patient taking medications prohibited by the protocol: corticosteroids by any route (except topical) from 4 weeks prior to screening; nonsteroidal anti-inflammatories or aspirin (greater than 100 mg per day) within 2 weeks prior to screening; paracetamol greater than 3000 mg per day within 2 weeks prior to screening; glucosamine or chondroitin sulfate within 2 weeks prior to screening; any local treatment i.a. into the knee within 3 months from screening.
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 15 days after stopping of investigational drug.
• Regular smokers (use of tobacco/nicotine products in the previous 3 months \> 5 cigarettes/day). Urine cotinine levels will be measured during screening for all subjects. Regular smokers will be defined as any subject who reports tobacco use of \> 5 cigarettes/day and/or who has a urine cotinine ≥ 500 ng/mL.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (2)

Novartis Investigative Site

Vienna, 1090, Austria

Location

Novartis Investigative Site

Vienna, 1180, Austria

Location

Related Links

• A Plain Language Trial Summary is available on novartisclinicaltrials.com

Results Point of Contact

• Title: Study Director
• Organization: Novartis Pharmaceuticals

novartis.email@novartis.com

862-778-8300

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2017
• First Posted: November 7, 2017
• Study Start: October 18, 2017
• Primary Completion: April 5, 2019
• Study Completion: April 5, 2019
• Last Updated: October 7, 2021
• Results First Posted: April 17, 2020

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will share

Locations

AU (2)